NEWPHARMA GROUP
Part of the group
236 companies in 18 countries
Board
7 directors, 1 in day-to-day management, 1 auditor, no change since 2023Director
since 20-01-2023
6-year term from 2023
also on the board of 28 other companies
listed in the 2026 annual accounts
Director
since 20-01-2023
6-year term from 2023
also on the board of 76 other companies
listed in the 2026 annual accounts
Director
since 20-01-2023
6-year term from 2023
also on the board of 46 other companies
listed in the 2026 annual accounts
Director
appointed by deed of 23-03-2023
6-year term from 2023
also on the board of 23 other companies
Managing director, permanent representative
appointed by deed of 12-10-2021
also on the board of 3 other companies
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Article 11. POUVOIR DE REPRÉSENTATION. L'organe d'administration représente la société à l'égard des tiers et en justice, en tant que…”deed of 20-11-2025
Permanent representatives 1
Mandates through the years
18 names, the dashed line is todayDirector
Director
Director
Director
Director
Director
Director
Managing director
Statutory auditor
Commissaire pour les comptes statutaires
Director
Class B director
Director
Class A director
Class B director
Class B director
Director
Director
LeadershipBoardEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
-
- Director, from 14-07-2021 to date
-
- Director, since before 31-12-2022
-
- Director, since before 31-12-2022
-
- Director, since before 31-12-2022
-
- Director, since before 31-12-2022
-
- Director, since before 31-12-2022
-
- Director, since before 31-03-2026
-
- Managing director, appointed by deed of 12-10-2021, still in office
-
- Statutory auditor, from 01-07-2023 to date
-
- Commissaire pour les comptes statutaires, appointed by deed of 15-01-2018, until 20-10-2023
-
- Director, from before 31-12-2022 to 23-03-2023
-
- Class B director, appointed by deed of 15-01-2018, until 23-03-2023
- Managing director, appointed by deed of 22-01-2018, until 14-07-2021
-
- Director, appointed by deed of 20-11-2017, until 23-03-2023
- Director, appointed by deed of 20-11-2017, no longer listed in the 2026 annual accounts
- Chair of the board, appointed by deed of 22-01-2018, no longer listed in the 2026 annual accounts
-
- Class A director, from 25-08-2021 to 23-03-2023
- Class A director, appointed by deed of 26-10-2021, no longer listed in the 2026 annual accounts
-
- Class B director, from 25-08-2021 to 23-03-2023
-
- Class B director, appointed by deed of 15-01-2018, until 23-03-2023
- Class B director, appointed by deed of 15-01-2018, no longer listed in the 2026 annual accounts
-
- Director, appointed by deed of 20-11-2017, until 01-08-2022
- Director, appointed by deed of 20-11-2017, no longer listed in the 2026 annual accounts
-
- Director, appointed by deed of 13-12-2018, no longer listed in the 2026 annual accounts
Control
Parent
Equity €295.9m
Profit €36,958 in 2026 (profit €190,124 in 2025)
Checked score
Source: own accounts 31-03-2026
100%
This company
NEWPHARMA GROUP
Equity €86.3m
Profit €138,686 in 2026
Further up the chain 100% 66.52%
Capital
- Capital
- €86,745,274
- Shares
- 67,500 in the 2026 annual accounts
- Contribution per share
- €1,285
- Equity per share
- €1,278 in 2026
- Source
- deed of 20-11-2025
Owners through the years
as the annual accounts name themOwners as a list
-
- 2018 to 2021: 26%
- 2022: 60.99%
-
- 2018 to 2021: 39%
- 2022: 39.01%
Source: shareholder structure in its own accounts, lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 20-11-2025 (in French)
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 3 directorsdeed of 20-11-2025 (in French)
- Financial instrumentThe company can also issue securities other than shares, such as bonds or warrants.
- “1 pour 1, conversion”deed of 12-02-2018 (in French)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Third Tuesday of September at 14:30deed of 20-11-2025 (in French)
Capital transactions
Shareholders according to the deeds
Stated in the deed
deed of 04-09-2025 ↗
- all shares
Stated in the deed
deed of 15-01-2018 ↗
- 26,325 shares
- 17,550 shares
At incorporation
deed of 20-11-2017 ↗
- 61 shares (98.4%)
- 1 share (1.6%)
Capital over time
- 20-11-2025 Capital stated in 2 deeds · €86,745,274 · 67,500 shares
- 04-04-2025 Capital increase of €7,000,000 · to €94,500,000 · in cash
- 04-04-2025 Capital reduction of €7,754,726 · to €86,745,274 · to absorb losses
- 07-04-2023 Capital increase of €20,000,000 · to €87,500,000 · no new shares · in cash
- 26-10-2021 Capital stated in 4 deeds · €67,500,000 · 67,500 shares
- 15-01-2018 Capital increase of €43,813,000 · 43,813 new shares at €1,000 per share · in cash
- 15-01-2018 Capital increase of €23,625,000 · 23,625 new shares at €1,000 per share · in cash
- 20-11-2017 Incorporation · €62,000 · 62 shares